October 2022, Vol 13, No 5

Although it is well established that air pollution is associated with lung cancer, how this occurs has not been well described. For the first time, researchers have identified the mechanism by which particulate matter in the air may lead to non–small-cell lung cancer (NSCLC) in people who have never smoked.

Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy.

More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi).

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.

For the first time, a novel gamma secretase inhibitor has shown extremely promising results in desmoid tumors—a rare, benign, but potentially aggressive tumor type

Digital health technologies have the potential to help transform patient care, but there are barriers that need to be overcome, said Deb Schrag, MD, MPH, George J.

The increased use of biosimilars within the US Oncology Network generated more than $6 million of savings in the Centers for Medicare & Medicaid Services’ Oncology Care Model (OCM) during the first half of 2020.

Minority and marginalized communities have historically been underrepresented in local and federal governments and in dozens of private sectors globally. Pharma is no different; there exists a steep chasm that drugmakers have yet to bridge concerning research and trials.

In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms.